Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.30 |
| ▸ | SELP | P16109 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30367972 | 1.00 | CA1 (0.40) | CA1CA2CA4CES2CES1 | |
| SCHEMBL516135 | 0.87 | ERN1 (0.39) | CA1CA2CA4CES2CES1 | |
| SCHEMBL5510282 | 0.81 | CA1 (0.40) | CA1CA2CA4CES2CES1 | |
| SCHEMBL5509678 | 0.81 | CES2 (0.38) | CA1CA2CA4CES2CES1 | |
| SCHEMBL78211 | 0.80 | CA1 (0.43) | CA1CA2CA4CES2CES1 | |
| SCHEMBL67874 | 0.79 | CA3 (0.36) | ERN1CA9CA3CA6CA5A | |
| SCHEMBL5948999 | 0.79 | ERN1 (0.34) | CA1CES2CES1ERN1CA12 | |
| SCHEMBL12459470 | 0.77 | CA1 (0.37) | CA1CA2CA4CES2CES1 | |
| SCHEMBL11432827 | 0.76 | ERN1 (0.39) | ERN1ESR1ESR2 | |
| SCHEMBL5948336 | 0.76 | PTGES (0.34) | CES2CES1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637438-B2 | Protoporphyrinogen oxidase inhibitors | ENKO CHEM, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250108124-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4484407-A2 | (METH)ACRYLATE COMPOUND, ADDITIVE FOR OPTICAL RESIN, OPTICAL ELEMENT, AND OPTICAL DEVICE | NIKON CORPORATION (JP) | 2025-01-01 | — | — | EP | disclosed |
| CN-118852275-A | Titanium-metallocene catalyst and preparation method and application thereof | 中山大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-116082563-B | (Meth) acrylate compound, optical resin additive, optical element, and optical device | 株式会社 尼康 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024175999-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2024-08-29 | — | — | WO | disclosed |
| EP-4402133-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | Enko Chem, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118359760-A | Optical resin, optical element, and optical device | 株式会社 尼康 | 2024-07-19 | — | — | CN | disclosed |
| CN-118265704-A | Protoporphyrinogen oxidase inhibitors | 恩科化学公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4340859-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | Biohaven Therapeutics Ltd. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2003084982-A2 | FUNCTIONALIZED COMPOSITIONS FOR IMPROVED IMMOBILIZATION | LUMINEX CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
| US-5248745-A | Copolymerization of dicyclopentadiene with norbornene derivatives | SHELL OIL COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5180867-A | COPOLYMERIZATION OF DICYCLOPENTADIENE WITH NORBORNENE DERIVATIVES | SHELL OIL COMPANY (US) | 1993-01-19 | — | — | US | disclosed |
| US-5093441-A | POLYMERIZATION OF NORBORNENE DERIVATIVES | SHELL OIL COMPANY (US) | 1992-03-03 | — | — | US | disclosed |
| US-5081208-A | Using a catalyst system comprising the reaction product of a tungsten compound and a halo- or trihalomethylphenol and a trihydrocarbyltin hydride; RIM; kinetics | SHELL OIL COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-4994426-A | Catalyst and process for polymerization of norbornene derivatives | SHELL OIL COMPANY (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0385556-A2 | Polymerization of bulky norbornene derivatives and polymers obtainable therewith | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-09-05 | — | — | EP | disclosed |
| EP-0372600-A2 | Copolymerization of dicyclopentadiene with norbornene derivatives and copolymers obtainable therewith | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-06-13 | — | — | EP | disclosed |
| US-4897255-A | Metal radionuclide labeled proteins for diagnosis and therapy | NEORX CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0336486-A2 | Polymerization of norbornene derivatives and catalytic system suitable for use therein | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108124-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | CD47, DOCK2, DOCK5 | CA1 1855/4885CA2 2542/4885CA4 1688/4885 |
| US-12637438-B2 | Protoporphyrinogen oxidase inhibitors | PPOX, CYP4X1, CBR3 | CA1 1168/4885CA2 288/4885CA4 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.